Active 0 6 0 6 O
malignancies 7 19 7 19 B-cancer
within 20 26 20 26 O
12 27 29 27 29 B-upper_bound
months 30 36 30 36 I-upper_bound
with 37 41 37 41 O
the 42 45 42 45 O
exception 46 55 46 55 O
of 56 58 56 58 O
those 59 64 59 64 O
with 65 69 65 69 O
a 70 71 70 71 O
negligible 72 82 72 82 O
risk 83 87 83 87 O
of 88 90 88 90 O
metastasis 91 101 91 101 B-cancer

Active 0 6 102 108 O
, 6 7 108 109 O
known 8 13 110 115 O
or 14 16 116 118 O
suspected 17 26 119 128 O
autoimmune 27 37 129 139 B-chronic_disease
disease 38 45 140 147 I-chronic_disease

Administration 0 14 148 162 O
of 15 17 163 165 O
a 18 19 166 167 O
live 20 24 168 172 B-treatment
vaccine 25 32 173 180 I-treatment
within 33 39 181 187 O
30 40 42 188 190 B-upper_bound
days 43 47 191 195 I-upper_bound
prior 48 53 196 201 I-upper_bound
to 54 56 202 204 O
first 57 62 205 210 O
dose 63 67 211 215 O
of 68 70 216 218 O
study 71 76 219 224 B-treatment
drug 77 81 225 229 I-treatment

Any 0 3 230 233 O
condition 4 13 234 243 O
requiring 14 23 244 253 O
concurrent 24 34 254 264 O
systemic 35 43 265 273 B-treatment
immunosuppressive 44 61 274 291 I-treatment
therapy 62 69 292 299 I-treatment

Arm 0 3 300 303 O
5 4 5 304 305 O
: 5 6 305 306 O
Received 7 15 307 315 O
at 16 18 316 318 O
least 19 24 319 324 O
one 25 28 325 328 O
prior 29 34 329 334 O
line 35 39 335 339 O
of 40 42 340 342 O
therapy 43 50 343 350 B-treatment
for 51 54 351 354 O
incurable 55 64 355 364 O
or 65 67 365 367 O
metastatic 68 78 368 378 B-cancer
NSCLC 79 84 379 384 I-cancer

Arm 0 3 385 388 O
5 4 5 389 390 O
: 5 6 390 391 O
Received 7 15 392 400 O
systemic 16 24 401 409 B-treatment
anticancer 25 35 410 420 I-treatment
therapy 36 43 421 428 I-treatment
within 44 50 429 435 O
21 51 53 436 438 B-upper_bound
days 54 58 439 443 I-upper_bound
prior 59 64 444 449 I-upper_bound
to 65 67 450 452 O
first 68 73 453 458 O
dose 74 78 459 463 O
of 79 81 464 466 O
study 82 87 467 472 O
drug 88 92 473 477 O

Arm 0 3 478 481 O
5 4 5 482 483 O
: 5 6 483 484 O
Suitable 7 15 485 493 O
for 16 19 494 497 O
treatment 20 29 498 507 O
with 30 34 508 512 O
nivolumab 35 44 513 522 B-treatment
per 45 48 523 526 O
package 49 56 527 534 O
insert 57 63 535 541 O

Arm 0 3 542 545 O
6 4 5 546 547 O
: 5 6 547 548 O
Documented 7 17 549 559 O
Stable 18 24 560 566 B-clinical_variable
Disease 25 32 567 574 I-clinical_variable
, 32 33 574 575 I-clinical_variable
Partial 34 41 576 583 I-clinical_variable
Response 42 50 584 592 I-clinical_variable
, 50 51 592 593 I-clinical_variable
Complete 52 60 594 602 I-clinical_variable
Response 61 69 603 611 I-clinical_variable
( 70 71 612 613 I-clinical_variable
SD 71 73 613 615 I-clinical_variable
/ 73 74 615 616 I-clinical_variable
PR 74 76 616 618 I-clinical_variable
/ 76 77 618 619 I-clinical_variable
CR 77 79 619 621 I-clinical_variable
) 79 80 621 622 I-clinical_variable
per 81 84 623 626 O
RECIST 85 91 627 633 O
1.1 92 95 634 637 O
after 96 101 638 643 O
a 102 103 644 645 O
minimum 104 111 646 653 O
of 112 114 654 656 O
9 115 116 657 658 B-lower_bound
to 117 119 659 661 O
12 120 122 662 664 B-upper_bound
weeks 123 128 665 670 I-upper_bound
of 129 131 671 673 O
front 132 137 674 679 B-treatment
line 138 142 680 684 I-treatment
immunotherapy 143 156 685 698 I-treatment
( 157 158 699 700 O
with 158 162 700 704 O
or 163 165 705 707 O
without 166 173 708 715 O
chemotherapy 174 186 716 728 B-treatment
) 186 187 728 729 O

Arm 0 3 730 733 O
6 4 5 734 735 O
: 5 6 735 736 O
Received 7 15 737 745 O
front 16 21 746 751 O
line 22 26 752 756 O
immunotherapy 27 40 757 770 B-treatment
( 41 42 771 772 O
with 42 46 772 776 O
or 47 49 777 779 O
without 50 57 780 787 O
chemotherapy 58 70 788 800 B-treatment
) 70 71 800 801 O
for 72 75 802 805 O
incurable 76 85 806 815 O
or 86 88 816 818 O
metastatic 89 99 819 829 B-cancer
NSCLC 100 105 830 835 I-cancer
and 106 109 836 839 O
did 110 113 840 843 O
not 114 117 844 847 O
progress 118 126 848 856 O
clinically 127 137 857 867 O

Arm 0 3 868 871 O
6 4 5 872 873 O
: 5 6 873 874 O
Suitable 7 15 875 883 O
for 16 19 884 887 O
front 20 25 888 893 B-treatment
line 26 30 894 898 I-treatment
maintenance 31 42 899 910 I-treatment
treatment 43 52 911 920 I-treatment
with 53 57 921 925 I-treatment
pembrolizumab 58 71 926 939 I-treatment
± 72 73 940 941 I-treatment
pemetrexed 74 84 942 952 I-treatment
per 85 88 953 956 O
the 89 92 957 960 O
current 93 100 961 968 O
approved 101 109 969 977 O
package 110 117 978 985 O
inserts 118 125 986 993 O

At 0 2 994 996 O
least 3 8 997 1002 O
one 9 12 1003 1006 B-lower_bound
site 13 17 1007 1011 O
of 18 20 1012 1014 O
measurable 21 31 1015 1025 O
disease 32 39 1026 1033 O
by 40 42 1034 1036 O
RECIST 43 49 1037 1043 O
1.1 50 53 1044 1047 O

Central 0 7 1048 1055 B-cancer
nervous 8 15 1056 1063 I-cancer
system 16 22 1064 1070 I-cancer
( 23 24 1071 1072 I-cancer
CNS 24 27 1072 1075 I-cancer
) 27 28 1075 1076 I-cancer
metastases 29 39 1077 1087 I-cancer
may 40 43 1088 1091 O
be 44 46 1092 1094 O
permitted 47 56 1095 1104 O
but 57 60 1105 1108 O
must 61 65 1109 1113 O
be 66 68 1114 1116 O
treated 69 76 1117 1124 O
and 77 80 1125 1128 O
neurologically 81 95 1129 1143 O
stable 96 102 1144 1150 O

Eastern 0 7 1151 1158 B-clinical_variable
Cooperative 8 19 1159 1170 I-clinical_variable
Oncology 20 28 1171 1179 I-clinical_variable
Group 29 34 1180 1185 I-clinical_variable
( 35 36 1186 1187 I-clinical_variable
ECOG 36 40 1187 1191 I-clinical_variable
) 40 41 1191 1192 I-clinical_variable
performance 42 53 1193 1204 I-clinical_variable
status 54 60 1205 1211 I-clinical_variable
( 61 62 1212 1213 I-clinical_variable
PS 62 64 1213 1215 I-clinical_variable
) 64 65 1215 1216 I-clinical_variable
of 66 68 1217 1219 O
0 69 70 1220 1221 B-lower_bound
or 71 73 1222 1224 O
1 74 75 1225 1226 B-upper_bound

Female 0 6 1227 1233 B-gender
patients 7 15 1234 1242 I-gender
who 16 19 1243 1246 O
are 20 23 1247 1250 O
of 24 26 1251 1253 O
childbearing 27 39 1254 1266 O
potential 40 49 1267 1276 O

Human 0 5 1277 1282 B-chronic_disease
immunodeficiency 6 22 1283 1299 I-chronic_disease
virus 23 28 1300 1305 I-chronic_disease
( 29 30 1306 1307 I-chronic_disease
HIV 30 33 1307 1310 I-chronic_disease
) 33 34 1310 1311 I-chronic_disease
, 34 35 1311 1312 O
hepatitis 36 45 1313 1322 B-chronic_disease
B 46 47 1323 1324 I-chronic_disease
or 48 50 1325 1327 I-chronic_disease
C 51 52 1328 1329 I-chronic_disease

Known 0 5 1330 1335 O
immunodeficiency 6 22 1336 1352 B-chronic_disease
disorders 23 32 1353 1362 I-chronic_disease
, 32 33 1362 1363 O
either 34 40 1364 1370 O
primary 41 48 1371 1378 O
or 49 51 1379 1381 O
acquired 52 60 1382 1390 O

Known 0 5 1391 1396 O
leptomeningeal 6 20 1397 1411 B-cancer
disease 21 28 1412 1419 I-cancer

Life 0 4 1420 1424 B-clinical_variable
expectancy 5 15 1425 1435 I-clinical_variable
≥18 16 19 1436 1439 O
weeks 20 25 1440 1445 I-lower_bound

Non 0 3 1446 1449 B-cancer
- 3 4 1449 1450 I-cancer
small 4 9 1450 1455 I-cancer
cell 10 14 1456 1460 I-cancer
lung 15 19 1461 1465 I-cancer
adenocarcinoma 20 34 1466 1480 I-cancer
or 35 37 1481 1483 O
squamous 38 46 1484 1492 B-cancer
cell 47 51 1493 1497 I-cancer
carcimona 52 61 1498 1507 I-cancer

Pregnant 0 8 1508 1516 B-pregnancy

Prior 0 5 1517 1522 O
participation 6 19 1523 1536 O
in 20 22 1537 1539 O
a 23 24 1540 1541 O
clinical 25 33 1542 1550 O
study 34 39 1551 1556 O
of 40 42 1557 1559 O
viagenpumatucel 43 58 1560 1575 B-treatment
- 58 59 1575 1576 I-treatment
L 59 60 1576 1577 I-treatment
( 61 62 1578 1579 I-treatment
HS-110 62 68 1579 1585 I-treatment
) 68 69 1585 1586 I-treatment

Refractory 0 10 1587 1597 O
to 11 13 1598 1600 O
prior 14 19 1601 1606 B-treatment
immunotherapy 20 33 1607 1620 I-treatment
( 34 35 1621 1622 O
clinical 35 43 1622 1630 B-treatment
or 44 46 1631 1633 I-treatment
radiographic 47 59 1634 1646 I-treatment
progression 60 71 1647 1658 I-treatment
after 72 77 1659 1664 B-upper_bound
12 78 80 1665 1667 I-upper_bound
weeks 81 86 1668 1673 I-upper_bound
or 87 89 1674 1676 O
less 90 94 1677 1681 O
of 95 97 1682 1684 O
immunotherapy 98 111 1685 1698 O
) 111 112 1698 1699 O

Significant 0 11 1700 1711 B-chronic_disease
cardiovascular 12 26 1712 1726 I-chronic_disease
disease 27 34 1727 1734 I-chronic_disease

Up 0 2 1735 1737 O
to 3 5 1738 1740 O
one 6 9 1741 1744 O
prior 10 15 1745 1750 O
line 16 20 1751 1755 O
of 21 23 1756 1758 O
checkpoint 24 34 1759 1769 B-treatment
inhibitor 35 44 1770 1779 I-treatment
therapy 45 52 1780 1787 I-treatment
is 53 55 1788 1790 O
permitted 56 65 1791 1800 O
( 66 67 1801 1802 O
must 67 71 1802 1806 O
have 72 76 1807 1811 O
received 77 85 1812 1820 O
at 86 88 1821 1823 O
least 89 94 1824 1829 O
4 95 96 1830 1831 B-lower_bound
months 97 103 1832 1838 I-lower_bound
of 104 106 1839 1841 O
treatment 107 116 1842 1851 B-treatment
) 116 117 1851 1852 O

Willing 0 7 1853 1860 O
to 8 10 1861 1863 O
provide 11 18 1864 1871 O
archival 19 27 1872 1880 O
or 28 30 1881 1883 O
fresh 31 36 1884 1889 O
tumor 37 42 1890 1895 B-treatment
biopsy 43 49 1896 1902 I-treatment
at 50 52 1903 1905 O
Screening 53 62 1906 1915 O

fertile 0 7 1916 1923 B-gender
male 8 12 1924 1928 I-gender
patients 13 21 1929 1937 I-gender
must 22 26 1938 1942 O
agree 27 32 1943 1948 B-contraception_consent
to 33 35 1949 1951 I-contraception_consent
use 36 39 1952 1955 I-contraception_consent
an 40 42 1956 1958 I-contraception_consent
effective 43 52 1959 1968 I-contraception_consent
form 53 57 1969 1973 I-contraception_consent
of 58 60 1974 1976 I-contraception_consent
contraception 61 74 1977 1990 I-contraception_consent
throughout 75 85 1991 2001 O
study 86 91 2002 2007 O
participation 92 105 2008 2021 O

fresh 0 5 2022 2027 B-treatment
tumor 6 11 2028 2033 I-treatment
biopsy 12 18 2034 2040 I-treatment
at 19 21 2041 2043 O
Week 22 26 2044 2048 O
10 27 29 2049 2051 O
when 30 34 2052 2056 O
feasible 35 43 2057 2065 O

radiographically 0 16 2066 2082 O
per 17 20 2083 2086 O
RECIST 21 27 2087 2093 O
1.1 28 31 2094 2097 O
at 32 34 2098 2100 O
first 35 40 2101 2106 O
imaging 41 48 2107 2114 O
assessment 49 59 2115 2125 O
, 59 60 2125 2126 O
and 61 64 2127 2130 O
will 65 69 2131 2135 O
begin 70 75 2136 2141 O
maintenance 76 87 2142 2153 O
immunotherapy 88 101 2154 2167 B-treatment
with 102 106 2168 2172 O
standard 107 115 2173 2181 O
of 116 118 2182 2184 O
care 119 123 2185 2189 O
pembrolizumab 124 137 2190 2203 B-treatment
± 138 139 2204 2205 O
pemetrexed 140 150 2206 2216 B-treatment

severe 0 6 2217 2223 B-chronic_disease
/ 6 7 2223 2224 I-chronic_disease
uncontrolled 7 19 2224 2236 I-chronic_disease
infections 20 30 2237 2247 I-chronic_disease
or 31 33 2248 2250 O
concurrent 34 44 2251 2261 B-chronic_disease
illness 45 52 2262 2269 I-chronic_disease
, 52 53 2269 2270 O
unrelated 54 63 2271 2280 O
to 64 66 2281 2283 O
the 67 70 2284 2287 O
tumor 71 76 2288 2293 B-cancer
, 76 77 2293 2294 O
requiring 78 87 2295 2304 O
active 88 94 2305 2311 B-treatment
therapy 95 102 2312 2319 I-treatment

